Worldwide Clinical Trials boosts exec team with new early-phase lead

Mike Mencer (Worldwide Clinical Trials)

Contract research organization Worldwide Clinical Trials has hired Mike Mencer as executive vice president and general manager of its early-phase services.

Mercer will be focusing on Worldwide’s bioanalysis lab in Austin, Texas, and the Clinical Pharmacology Unit clinic in San Antonio. This has a focus on early-stage, typically phase 1, trials.

“Mencer and the Worldwide team will continue to leverage an agile and responsive strategy with experience in study design and operations to ensure maximum trial value and seamless linkage with later-stage studies,” the company said in a statement.  

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

He comes from AES, a business unit from rival biopharma services firm PPD, where he was most recently executive director of business development operations.

Peter Benton, president and chief operating officer at Worldwide Clinical Trials, said: “The biopharma industry is seeking a specialized and personal CRO in their Phase I providers that can provide the expertise they need to develop their molecule further. Mike is the perfect addition to our team to make it happen. Mike’s passion for optimization and operational excellence is well suited to our Early Phase team. We are beyond thrilled to have him on board to move our Phase I team forward.”

“I’m excited to join this uncommon team. I truly appreciate Worldwide’s commitment to excellence and pioneering spirit that makes them a leader in the midsize CRO space,” added Mencer.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.